Acadia Pharmaceuticals (ACAD) Shares Outstanding (2010 - 2026)

Acadia Pharmaceuticals' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $171.1 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 2.38% year-over-year to $171.1 million; the TTM figure through Mar 2026 stood at $171.1 million (up 2.38% YoY), while the FY2025 annual figure was $170.3 million, up 2.16% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $171.1 million, roughly flat from $170.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $171.1 million in Q1 2026, with the low at $161654.0 in Q2 2022.
• The 5-year median for Shares Outstanding (Entity) is $165.0 million (2024), against an average of $107.9 million.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) tumbled 99.9% in 2022, then surged 101664.05% in 2024.
• Acadia Pharmaceuticals' Shares Outstanding (Entity) stood at $161683.0 in 2022, then rose by 1.32% to $163819.0 in 2023, then soared by 101664.05% to $166.7 million in 2024, then increased by 2.16% to $170.3 million in 2025, then rose by 0.46% to $171.1 million in 2026.
• Business Quant data shows ACAD's Shares Outstanding (Entity) at $171.1 million in Q1 2026, $170.3 million in Q4 2025, and $169.1 million in Q3 2025.